ArticleOpen forum infectious diseases2025
Estimation of General Practitioner Visits, Hospitalizations and Deaths Attributable to Respiratory Syncytial Virus and Influenza Virus, and Costs Associated With Hospitalizations, in Older Adults in France From 2010 to 2020.
Article in Open forum infectious diseases, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Respiratory syncytial virus in adults aged ≥ 50 years in France: a database and time-series modelling analysis (2014-2020).Infection · 2026Observational
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Respiratory syncytial virus (RSV) and influenza virus are leading causes of respiratory infections, causing substantial numbers of hospitalizations and deaths, particularly among vulnerable groups such as infants and older adults. While the burden of influenza virus infection is well-documented, the burden of RSV infection in the adult population is often underestimated due to diagnostic challenges and infrequent standard-of-care testing. This study aimed to estimate the incidence of general practitioner (GP) visits, hospitalizations, and deaths attributable to RSV and influenza virus infections in French adults aged ≥50 years, with a focus on ≥65 years, using a time-series model-based approach. In addition, costs associated with hospitalizations were calculated. Methods: Cyclic Poisson regression models and weekly data from French medical administrative databases and electronic medical records over ten epidemic seasons (2010-2020) were used to estimate incidences for RSV and influenza. The results were stratified by age group, diagnosis causes (respiratory and cardiorespiratory) and diagnosis type (primary and secondary). Average costs per hospitalization were calculated and multiplied by the number of hospitalizations estimated. Results: Among adults aged ≥65 years, we estimated RSV infection was responsible for 647 619 GP visits 24 319 hospitalizations, and 878 deaths per year. Incidence rates for GP visits for RSV were twice as large as for influenza; hospitalization rates were similar and mortality was lower. The mean annual cost of RSV-attributable hospitalizations was 105 million €, similar to influenza. Conclusions: This study highlighted the burden of RSV disease in the adult population in France is higher than previous reported. We envisage that this model-based approach will be instrumental in evaluating the impact of RSV vaccination campaigns.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.